Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Black

Gastroenterology Norman, OK Medical Doctor

NPI 1851392351 CMS profile 356189

1125 N Porter Ave Ste 301, Norman, OK 73071

Open in the dashboard

General payments

$21,313

203 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Black of Norman, OK is reported in the CMS Open Payments database as having received $21,313 across 203 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16 1
2024 General $34 1
2023 General $19 1
2021 General $3,650 22
2020 General $5,947 27
2019 General $11,647 151

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Black
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Andrew Black were reported at $16. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Andrew Black Gastroenterology median Middle half National median
2019 $11,647 $417 $126–$1,100 $163
2020 $5,947 $224 $74–$624 $114
2021 $3,650 $352 $106–$1,054 $132
2022 $0 $448 $129–$1,270 $149
2023 $19 $533 $150–$1,390 $160
2024 $34 $605 $160–$1,606 $164
2025 $16 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $16,539 45 payments
  2. Allergan Inc. $2,922 22 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $350 25 payments
  4. Janssen Biotech, Inc. $303 22 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $265 16 payments
  6. Merck Sharp & Dohme Corporation $205 17 payments
  7. Pfizer Inc. $133 14 payments
  8. Romark Laboratories, LC $123 9 payments
  9. Gilead Sciences, Inc. $94 8 payments
  10. Intercept Pharmaceuticals, Inc. $74 5 payments
  11. Other $305 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $18,250 13 payments
  2. Food and Beverage $3,063 190 payments
Products named General payments · program years 2019–2025
  1. LINZESS $7,299 33 payments
  2. CREON $4,916 18 payments
  3. VIBERZI $1,260 12 payments
  4. STELARA $303 22 payments
  5. XIFAXAN $260 18 payments
  6. RENFLEXIS $171 16 payments
  7. ALINIA Gastroenterology $123 9 payments
  8. ALINIA Gastroenterology $123 9 payments
  9. ALINIA Gastroenterology $123 9 payments
  10. Entyvio $108 7 payments
  11. Other $1,244 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

203 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record